Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Top drugs : history, pharmacology, syntheses / / Jie Jack Li
| Top drugs : history, pharmacology, syntheses / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (219 p.) |
| Disciplina | 615.1 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Drugs - History
Drugs - Design Pharmaceutical chemistry |
| ISBN |
0-19-756291-4
0-19-936260-2 0-19-936259-9 |
| Classificazione | MED071000SCI013060 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS
3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS 4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases Chapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPARγ Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors 1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS 3.1 Discovery Route |
| Record Nr. | UNINA-9910797122703321 |
Li Jie Jack
|
||
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Top drugs : history, pharmacology, syntheses / / Jie Jack Li
| Top drugs : history, pharmacology, syntheses / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (219 p.) |
| Disciplina | 615.1 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Drugs - History
Drugs - Design Pharmaceutical chemistry |
| ISBN |
0-19-756291-4
0-19-936260-2 0-19-936259-9 |
| Classificazione | MED071000SCI013060 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS
3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS 4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases Chapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPARγ Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors 1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS 3.1 Discovery Route |
| Record Nr. | UNINA-9910826031703321 |
|
Li Jie Jack
|
||
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Triumph of the heart [[electronic resource] ] : the story of statins / / Jie Jack Li
| Triumph of the heart [[electronic resource] ] : the story of statins / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, : Oxford University Press, 2009 |
| Descrizione fisica | 1 online resource (220 p.) |
| Disciplina | 615/.718 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Statins (Cardiovascular agents) - History
Anticholesteremic agents |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-19-756250-7
0-19-988665-2 1-281-99848-6 9786611998486 0-19-804351-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Foreword; Contents; 1 Cholesterol; The Janus-Faced Molecule; One of the 10 Greatest Discoveries in Medicine; The Good, the Bad, and the Ugly; Hitler's Gift; The Framingham Heart Study; The Receptor; 2 Genesis of Statins; Early Cholesterol Drugs; Nicotinic acid; Resins; Fibrates; I Refuse to Sign Th is Report!; Birth of Statins; Endo's discovery of the first statin; The fate of mevastatin; Endo's fate; How do statins work?; 3 Merck's Triumph; Merck; Humble beginnings; George W. Merck; Penicillin; Cortisone; Streptomycin; Glorious history; Mevacor and Zocor; The poor Greek immigrant kid
PreludeDiscovery; Halt!; Triumph; The Company, the Drugs, and the Inventors Today; 4 Discovery of Lipitor; Splendid History; Parke, Davis & Company; Dilantin; Chloromycetin; The pill; Lopid; Roger S. Newton; Bruce D. Roth; The Discovery of Lipitor; Shoulders of giants; The first success . . . and disappointment; The second refrain; CI-971; CI-981; 5 Development of Lipitor; Checkered Life; Chiral or Not, You Have to Make It First; Clinical Trials-Divine Providence?; Canter and the FDA; What's in a Name?; A Marketing Partner; 6 To Market, to Market; Pfizer Inc. The small drug firm in Brooklyn made bigPenicillin; Drugs of its own; Windfall: The Era of Blockbusters; Viagra; Zoloft; Diflucan; Zithromax; Norvasc; The Merger; PROVE-IT; The Patent Litigation; 7 Baycol, Crestor, and Cholesterol Drugs beyond Statins; The Story of Baycol; Crestor; Cholesterol Drugs beyond Statins; Zetia and Vytorin; Torcetrapib, a bitter disappointment; ApoA-1 Milano and Newton; 8 Reflections; Triumph of the Heart; Statins set a high standard in efficacy; Statins set a high standard in safety; Statins set a high standard in financial benefits The Drug Industry and the Blockbuster ModelAppendix: Drug Names; Notes and References; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z |
| Record Nr. | UNINA-9910454399103321 |
|
Li Jie Jack
|
||
| New York, : Oxford University Press, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Triumph of the heart [[electronic resource] ] : the story of statins / / Jie Jack Li
| Triumph of the heart [[electronic resource] ] : the story of statins / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, : Oxford University Press, 2009 |
| Descrizione fisica | 1 online resource (220 p.) |
| Disciplina | 615/.718 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Statins (Cardiovascular agents) - History
Anticholesteremic agents |
| ISBN |
0-19-756250-7
0-19-988665-2 1-281-99848-6 9786611998486 0-19-804351-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Foreword; Contents; 1 Cholesterol; The Janus-Faced Molecule; One of the 10 Greatest Discoveries in Medicine; The Good, the Bad, and the Ugly; Hitler's Gift; The Framingham Heart Study; The Receptor; 2 Genesis of Statins; Early Cholesterol Drugs; Nicotinic acid; Resins; Fibrates; I Refuse to Sign Th is Report!; Birth of Statins; Endo's discovery of the first statin; The fate of mevastatin; Endo's fate; How do statins work?; 3 Merck's Triumph; Merck; Humble beginnings; George W. Merck; Penicillin; Cortisone; Streptomycin; Glorious history; Mevacor and Zocor; The poor Greek immigrant kid
PreludeDiscovery; Halt!; Triumph; The Company, the Drugs, and the Inventors Today; 4 Discovery of Lipitor; Splendid History; Parke, Davis & Company; Dilantin; Chloromycetin; The pill; Lopid; Roger S. Newton; Bruce D. Roth; The Discovery of Lipitor; Shoulders of giants; The first success . . . and disappointment; The second refrain; CI-971; CI-981; 5 Development of Lipitor; Checkered Life; Chiral or Not, You Have to Make It First; Clinical Trials-Divine Providence?; Canter and the FDA; What's in a Name?; A Marketing Partner; 6 To Market, to Market; Pfizer Inc. The small drug firm in Brooklyn made bigPenicillin; Drugs of its own; Windfall: The Era of Blockbusters; Viagra; Zoloft; Diflucan; Zithromax; Norvasc; The Merger; PROVE-IT; The Patent Litigation; 7 Baycol, Crestor, and Cholesterol Drugs beyond Statins; The Story of Baycol; Crestor; Cholesterol Drugs beyond Statins; Zetia and Vytorin; Torcetrapib, a bitter disappointment; ApoA-1 Milano and Newton; 8 Reflections; Triumph of the Heart; Statins set a high standard in efficacy; Statins set a high standard in safety; Statins set a high standard in financial benefits The Drug Industry and the Blockbuster ModelAppendix: Drug Names; Notes and References; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z |
| Record Nr. | UNINA-9910782880803321 |
|
Li Jie Jack
|
||
| New York, : Oxford University Press, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Triumph of the heart : the story of statins / / Jie Jack Li
| Triumph of the heart : the story of statins / / Jie Jack Li |
| Autore | Li Jie Jack |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | New York, : Oxford University Press, 2009 |
| Descrizione fisica | 1 online resource (220 p.) |
| Disciplina | 615/.718 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Statins (Cardiovascular agents) - History
Anticholesteremic agents |
| ISBN |
0-19-756250-7
0-19-988665-2 1-281-99848-6 9786611998486 0-19-804351-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Foreword; Contents; 1 Cholesterol; The Janus-Faced Molecule; One of the 10 Greatest Discoveries in Medicine; The Good, the Bad, and the Ugly; Hitler's Gift; The Framingham Heart Study; The Receptor; 2 Genesis of Statins; Early Cholesterol Drugs; Nicotinic acid; Resins; Fibrates; I Refuse to Sign Th is Report!; Birth of Statins; Endo's discovery of the first statin; The fate of mevastatin; Endo's fate; How do statins work?; 3 Merck's Triumph; Merck; Humble beginnings; George W. Merck; Penicillin; Cortisone; Streptomycin; Glorious history; Mevacor and Zocor; The poor Greek immigrant kid
PreludeDiscovery; Halt!; Triumph; The Company, the Drugs, and the Inventors Today; 4 Discovery of Lipitor; Splendid History; Parke, Davis & Company; Dilantin; Chloromycetin; The pill; Lopid; Roger S. Newton; Bruce D. Roth; The Discovery of Lipitor; Shoulders of giants; The first success . . . and disappointment; The second refrain; CI-971; CI-981; 5 Development of Lipitor; Checkered Life; Chiral or Not, You Have to Make It First; Clinical Trials-Divine Providence?; Canter and the FDA; What's in a Name?; A Marketing Partner; 6 To Market, to Market; Pfizer Inc. The small drug firm in Brooklyn made bigPenicillin; Drugs of its own; Windfall: The Era of Blockbusters; Viagra; Zoloft; Diflucan; Zithromax; Norvasc; The Merger; PROVE-IT; The Patent Litigation; 7 Baycol, Crestor, and Cholesterol Drugs beyond Statins; The Story of Baycol; Crestor; Cholesterol Drugs beyond Statins; Zetia and Vytorin; Torcetrapib, a bitter disappointment; ApoA-1 Milano and Newton; 8 Reflections; Triumph of the Heart; Statins set a high standard in efficacy; Statins set a high standard in safety; Statins set a high standard in financial benefits The Drug Industry and the Blockbuster ModelAppendix: Drug Names; Notes and References; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z |
| Record Nr. | UNINA-9910824139503321 |
|
Li Jie Jack
|
||
| New York, : Oxford University Press, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
